


**French National Agency for Medicines and Health Products Safety**

CERTIFICATE NUMBER: 16MPP048HVFR02

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1, 2}**Part 1**

Issued following an inspection in accordance with :

Art. 111(5) of Directive 2001/83/EC as amended

Art. 80(5) of Directive 2001/82/EC as amended

The competent authority of France confirms the following:

The manufacturer: **FINORGA**

Site address: **Dynamic Synthesis Finorga, avenue du Lac, BP 30, MOURENX, 64150, France**

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC and Art. 80(1) of Directive 2001/82/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2016-06-23** , it is considered that it complies with :

- The principles of GMP for active substances³ referred to in Article 47 of Directive 2001/83/EC and Article 51 of Directive 2001/82/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Manufacture of active substance. Names of substances subject to inspection :

AMISULPRIDE(en)

BETAHISTINE DIHYDROCHLORIDE(en)

BETAXOLOL HYDROCHLORIDE(en)

DILTIAZEM HYDROCHLORIDE(en)

METOCLOPRAMIDE(en)

METOCLOPRAMIDE HYDROCHLORIDE(en)

PINAVERIUM BROMIDE(en)

SULPIRIDE(en)

TIAPRIDE HYDROCHLORIDE(en)

EICOSAPENTAENOIC ACID ETHYL ESTER(en)

LACOSAMIDE(en)

SAXAGLIPTIN HYDROCHLORIDE(en)

SERTRALINE(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : AMISULPRIDE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

Active Substance : BETAHISTINE DIHYDROCHLORIDE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for

	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : BETAXOLOL HYDROCHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Active Substance : DILTIAZEM HYDROCHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : METOCLOPRAMIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material

	which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : METOCLOPRAMIDE HYDROCHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : PINAVERIUM BROMIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : SULPIRIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization

3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : TIAPRIDE HYDROCHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : EICOSAPENTAENOIC ACID ETHYL ESTER	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.3 Salt formation / Purification steps : Chromatography
3.2	Extraction of Active Substance from Natural Sources
	3.2.2 Extraction of substance from animal source
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Active Substance : LACOSAMIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.2 Manufacture of crude active substance

	3.1.3 Salt formation / Purification steps : Crystallization
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : SAXAGLIPTIN HYDROCHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : SERTRALINE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

Clarifying remarks (for public users)

Period of validity of the certificate extended to 19 June 2020; SERTRALINE : Limited to the manufacturing of intermediate 4S-Tetralone; SAXAGLIPTIN HYDROCHLORIDE : Limited to the manufacturing of intermediate (3-Hydroxy-tricyclo [3.3.1.1(3,7)] decan-1-yl) oxo acetic acid; The intermediate Clomesac of the Active Substance METOCLOPRAMIDE is isolated and marketed. / Signatory : Mrs Linda Gallais, head of starting materials inspection department --- The ANSM does not issue hard copies of good practices certificates

2019-11-18

Name and signature of the authorised person of the
Competent Authority of France

Confidential
French National Agency for Medicines and Health
Products Safety
Tel: *Confidential*
Fax: *Confidential*



APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. République française **SAZi**
- Le présent acte public
2. a été signé par... **Me Delegge de Vertean**
3. agissant en qualité de... **Notaire**
4. est revêtu du sceau/timbre de... **Son étude**

Attesté

5. à Paris **21 OCT. 2020**
6. le... **M. LERNOUT**
7. par le Procureur général près la **Cour d'appel de Paris**

8. sous n° **10781**
9. Sceau :
10. Signature : **Michel LERNOUT**
PREMIER AVOCAT GENERAL

"L'Apostille confirme seulement l'authenticité de la signature, du sceau ou timbre sur le document. Elle ne signifie pas que le contenu du document est correct ou que la République française approuve son contenu"

